Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.
Ontology highlight
ABSTRACT: Rates of major depressive disorder (MDD) are disproportionally high in subjects with opioid use disorder (OUD) relative to the general population. MDD is often more severe in OUD patients, leading to compliance issues with maintenance therapies and poor outcomes. A growing body of literature suggests that endogenous opioid system dysregulation may play a role in the emergence of MDD. Buprenorphine, a mixed opioid receptor agonist/antagonist approved for the treatment of OUD and chronic pain, may have potential as a novel therapeutic for MDD, especially for patients with a dual diagnosis of MDD and OUD. This paper presents a comprehensive review of papers relevant to the assessment of buprenorphine as a treatment for MDD, OUD, and/or suicide compiled using electronic databases per Preferred
SUBMITTER: Namchuk AB
PROVIDER: S-EPMC9518754 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA